Kasper, B., Ratan, R., Alcindor, T., Schoeffski, P., van der Graaf, W. T. A., Wilky, B. A., … Gounder, M. M. (2022). LBA2 DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT). In Annals of Oncology (Vol. 33, pp. S1435–S1436). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.08.075

Kasper, B., R. Ratan, T. Alcindor, P. Schoeffski, W. T. A. van der Graaf, B. A. Wilky, R. F. Riedel, et al. “LBA2 DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT).” In Annals of Oncology, 33:S1435–36. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.08.075.

Kasper B, Ratan R, Alcindor T, Schoeffski P, van der Graaf WTA, Wilky BA, et al. LBA2 DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT). In: Annals of Oncology. Elsevier BV; 2022. p. S1435–6.

Kasper, B., et al. “LBA2 DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT).” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S1435–36. Crossref, doi:10.1016/j.annonc.2022.08.075.

Kasper B, Ratan R, Alcindor T, Schoeffski P, van der Graaf WTA, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S, Attia S, Chawla SP, D’Amato G, Federman N, Van Tine P, Van Tine BA, Vincenzi B, Kummar S, Gounder MM. LBA2 DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT). Annals of Oncology. Elsevier BV; 2022. p. S1435–S1436.